Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of NBTXR3 Activated by SABR for Patients With Advanced HNSCC or NSCLC Treated With an Anti-PD1 Antibody

Trial Profile

A Phase I/II Study of NBTXR3 Activated by SABR for Patients With Advanced HNSCC or NSCLC Treated With an Anti-PD1 Antibody

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2018

At a glance

  • Drugs NBTXR 3 (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Nanobiotix
  • Most Recent Events

    • 04 Jul 2018 Status changed from planning to not yet recruiting.
    • 26 Dec 2017 According to a Nanobiotix media release, the first patient first visit in the potentially paradigm changing trial is expected in Q2 2018 with with first expected results in the summer of 2019.
    • 26 Dec 2017 According to a Nanobiotix media release, the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application for NBTXR3 for the conduct of this trial. The trial will be led by coordinating investigator Tanguy Seiwert, M.D., of The University of Chicago Medical Center, and principal investigator Jared Weiss, M.D., of The University of North Carolina - Chapel Hill.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top